pharma · Obesity, Overweight · Type 2 Diabetes
Eli Lilly and
Eli Lilly Co.
Eli Lilly Co is a pharma organization headquartered in EU. Primary therapeutic focus areas include Obesity, Overweight, Type 2 Diabetes, Ulcerative Colitis, Type 2 Diabetes Mellitus, Breast Cancer. NovaPharmaNews links 1
Company details
- Status
- Public
- HQ
- Lilly Corporate Center, Indianapolis, Indiana 46285, US
- Founded
- 1876
- Employees
- 55,860
- Programs
- 107
- Drugs
- 99
- Patents
- 0
LOXO-FRA-24001
Phase 1 · other · Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lung cancer, triple-negative breast cancer, pancreatic cancer and colorectal cancer.
LOXO-FRA-24001 for Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lung cancer, triple-negative breast cancer, pancreatic cancer and colorectal cancer. is a Phase 1 program (other) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Internal code LOXO-FRA-24001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Eli Lilly Co.
- Phase
- Phase 1
- Modality
- other
- Indication
- Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lung cancer, triple-negative breast cancer, pancreatic cancer and colorectal cancer.
- Status
- active
- Trials
- 1